Table 1 Clinical and demographic characteristics
Data/subgroups | No CHT (n = 14) | CHT (n = 14) | p Value a |
|---|---|---|---|
Age (years) | 52 ± 10 | 52 ± 10 | 1.00 |
Gender (M/F) | 11/3 | 11/3 | 1.00 |
Education (years) | 14 ± 5 | 14 ± 5 | 0.96 |
Type (HL/NHL) | 2/12 | 2/12 | 1.00 |
Age at onset (years) | 52 ± 10 | 51 ± 9 | 0.96 |
PET localization outside brain (yes/no) | 11/3 | 4/10 | 0.01 |
Lymphoma symptoms (yes/no) | 5/9 | 5/9 | 1.00 |
Cycles number (n) | - | 6 ± 3 | - |
Post-CHT time (months) | - | 7 ± 9 | - |
First-line treatmentb (n) | - | 9 | - |
Second-line treatment (n) | - | 5 | - |
Immunochemotherapy (n) | - | 10 (7/3)c | - |
MMSE/30 | 28.4 ± 1.3 | 28.1 ± 1.1 | 0.63 |
HADS depression/21 | 4 ± 3 | 4 ± 3 | 0.86 |
HADS anxiety/21 | 6 ±3 | 4 ±3 | 0.17 |
MADRS/50 | 9 ± 6 | 8 ± 7 | 0.68 |
DT/10 | 3 ±2 | 2 ±2 | 0.28 |